Introduction
Capsaicin is a homovanillic acid derivative (trans-8-methyl-Nvanillyl-6-nonenamide) and a pungent ingredient found mostly in hot chili pepper. Recent reports have demonstrated that it has chemopreventive and chemotherapeutic activities in various cancer models (1) (2) (3) (4) (5) (6) . In an in vivo study, capsaicin treatment suppressed azoxymethane-induced aberrant cryptic foci formation in rats (7) . Various mechanisms of capsaicin-induced apoptosis have also been proposed from different cancer cell models. Capsaicin induces apoptosis through activation of caspase-3 and the intracellular Ca 2þ release pathway in esophagus carcinoma cells (3) . In leukemia, capsaicin induces apoptosis through a p53-dependent mechanism (5), but in prostate cancer cells, capsaicin's effect is p53 independent (2) . Capsaicin-induced apoptosis is elevated by co-treatment of the adenosine monophosphate-activated protein kinase activator in colorectal cancer cells (8) . Thus, it is likely that various mechanisms are involved in capsaicin-induced apoptosis, and the efficacy of capsaicin is dependent on cell or tissue context.
Non-steroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) is a member of the transforming growth factor b superfamily and is cloned by our group from cyclooxygenase deficient human colorectal cancer cells (9) . Expression of the full-length NAG-1 protein results in increased apoptosis and decreased tumor size in the xenograft mouse model (9) . Results from our previous study indicated that transgenic mice overexpressing NAG-1 (NAG-Tg) were resistant to azoxymethane-induced aberrant cryptic foci, and NAG-Tg/ APC Minþ mice showed less tumor load in the small intestine compared with littermate APC Minþ control mice (10) . Recently, we have also shown that NAG-1 expression causes less tumor formation in urethane-induced lung tumor model (11) . Thus, NAG-1 expression results in a suppression of tumor formation in colon and lung cancer animal models. Along with these findings, we have also reported that NAG-1 expression is induced not only by NSAIDs (9, 12) but also by several antitumorigenic compounds, including PPARc ligands (13) , and dietary chemopreventive compounds, such as conjugated linoleic acid (14) , indole-3-carbinol (15), 6-gingerol (16) , resveratrol (17) , catechins (18) , and genistein (19) . NAG-1 expression is mediated by a tumor suppressor protein such as p53 (17, 19) , early growth response gene-1 (12, 20) , glycogen synthase kinase 3b (GSK3b) (21) , and activating transcription factor 3 (ATF3) (14) . These results indicate that NAG-1 serves as a tumor suppressor gene and a target protein of several chemopreventive compounds (22) .
The current study was performed to examine the role of NAG-1 in capsaicin-induced apoptosis and the molecular mechanisms by which capsaicin induces NAG-1 expression in human colorectal cancer cells. Here, we report for the first time that treating cells with capsaicin results in an increase of NAG-1 expression through GSK3b/C/EBPband Protein Kinase C (PKC)d/C/EBPb-mediated pathways, and ATF3 is positively interacted with C/EBPb activity.
Materials and Methods

Materials
Human colorectal cancer cells (HCT-116, SW480, HT-29, and LoVo) were purchased from American Type Culture Collection (Manassas, VA), and culture media were purchase from Bio Whittaker (Rockland, ME). Capsaicin was purchased from Biomol (Plymouth Meeting, PA) and dissolved in ethanol. RO-31-8220, rottlerin, PD98059, SP600125, SB203585, AG490, MG132, wortmannin, AR-A014418, and rapamycin were purchased from Calbiochem (San Diego, CA). Antibody for Sp1 was purchased from Upstate (Lake Placid, NY) and antibodies for C/EBPa, C/EBPb, cAMP response element binding (CREB), retinoic acid receptora (RARa), ATF3, p53, actin and ATF3 small interfering RNA (siRNA) were purchased from Santa Cruz (Santa Cruz, CA). Antibody for phosphor-Ser/Thr was purchased from BD Bioscience (San Jose, CA) and antibody for GSK3b and GSK3b siRNA were purchased from Cell Signaling (Beverly, MA). The antibody for V5 was purchased from Invitrogen (Carlsbad, CA) and NAG-1 antibody was described previously (9) . Control and C/EBPb short hairpin RNA (shRNA) was kindly provided by Dr Jessica Schwartz (University of Michigan, Ann Arbor, MI). All chemicals were purchased from Fisher Scientific (Pittsburgh, PA), unless otherwise specified.
Cell culture HCT-116 and HT-29 cells were maintained in McCoy's 5A medium, and SW480 and LoVo cells were maintained in RPMI and Ham's F-12 medium, respectively. All media contained 10% fetal bovine serum. The cells were treated with capsaicin under serum-free media for 6-24 h as indicated in the figure 1-6 legends.
Human NAG-1 promoters
The NAG-1 promoters were described previously (23) . Internal deletion clones were created using QuikChange II mutagenesis kit (Stratagene, La Jolla, CA) with the following primers: pNAG-1D-110/-103, forward 5#-cacccccagaccccgcccagcttggagtgttt-3#, and reverse 5#-gcctgcagagtaaacactccaagctgggcggggtc-3#; pNAG-1D-87/-80, forward 5#-tgtggtcattggagtg tttactcgggggaggaggg-3#, and reverse 5#-gctcagtccc gccctcctcccccgagtaaac-3#.
Expression vectors
Full-length C/EBPa, C/EBPd, and CHOP (C/EBPf) cDNAs were amplified from human lung cDNA (Clontech, Mountain View, CA) using ReadyMix Taq polymerase (Sigma, St Louis, MO) with the following primers: C/EBPa, forward 5#-tgccgggagaactctaactc-3#, and reverse 5#-caccggaatctcctagtcctg-3#; C/EBPd, forward 5#-aggtgacagcctcgcttg-3#, and reverse 5#-gtatgggtcg ttgctgagtctct-3#; CHOP, forward 5#-agactgatccaac tgcagag-3#, and reverse 5#-tgcttggtgcagattcacc-3#. Polymerase chain reaction (PCR) was performed for 30 cycles at 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min. PCR product of C/EBPa, C/EBPd, and CHOP were subcloned into pcDNA3.1/V5/ His TOPO vector (Invitrogen) to generate the V5-His-tagged clones, pcDNA3.1/C/EBPa/V5/His, pcDNA3.1/C/EBPd/V5/His, and pcDNA3.1/ CHOP/V5/His, respectively. For C/EBPb expression vector, pOTB7 vector containing full length C/EBPb cDNA (Open Biosystems, Huntsville, AL) were digested using EcoRI and XhoI and subcloned into pcDNA3.1 (Invitrogen) to generate pcDNA3.1/C/EBPb. For cloning of N-terminally truncated C/EBPb (C/EBPb2) expression vector (24) , PCR was performed using pcDNA3.1/C/ EBPb with forward primer (5#-ccccctgccgccgccgccgcctgc-3#) and reverse primer (5#-gcagtggccggaggaggcg-3#) and subcloned into pcDNA3.1/V5/His TOPO vector (Invitrogen) to generate pcDNA3.1/C/EBPb2/V5/His. For GSK3b expression vector, full length of GSK3b cDNA were cloned into pcDNA3.1/V5/His TOPO vector to make pcDNA3.1/GSK3b/V5/His with forward primer (5#-gaaggaaaaggtgattcgcgaagag-3#) and reverse primer (5#-ggtggagttggaagctgatgcagaa-3#). CREB expression vector was kindly provided by Dr Joo-Heon Yoon (Yonsei University, Seoul, Korea), and Sp1 expression vector was previously described (23) . The pCMX-hRARa expression vector was kindly provided by Dr Ronald M. Evans (The Salk Institute for Biological Studies).
Flow cytometric detection of apoptotic cells
The cells were plated in six-well tissue culture dishes and incubated with capsaicin. The attached and floating cells were collected, washed with phosphate-buffered saline (PBS), resuspended in 80% ice-cold ethanol, and kept at À20°C overnight. The cells were rehydrated with PBS and stained with 70 lM propidium iodide solution including 1 mg/ml RNase A. Apoptosis and cell cycle distribution were analyzed using Beckman Coulter Epixs XL flow cytometer (Brea, CA) equipped with EXPO32 ADC and ModiFit LT software, respectively.
Transient transfections
Transient transfections were performed using Lipofectamine (Invitrogen) according to the manufacturer's instructions. The cells were plated in 12-well plates at the concentration of 2 Â 10 5 cells per well. The next day, plasmid mixtures containing 0.5 lg of NAG-1 promoter and 0.05 lg of pRL-null vector were co-transfected for 5 h in serum-free media. For the co-transfection experiment, 0.25 lg of NAG-1 promoter and 0.25 lg of expression vectors were co-transfected with 0.05 lg of pRL-null vector. After refreshment overnight, the transfected cells were exposed to ethanol or capsaicin for 24 h. The cells were harvested in 1Â luciferase lysis buffer (Promega, Madison, WI), and luciferase activity was measured and presented as a ratio of firefly luciferase signal/renilla luciferase signal using a dual luciferase assay kit (Promega).
Reverse transcription-polymerase chain reaction Total RNA was prepared using RNA isolation kit (Eppendorf, Hamburg, Germany) and reverse-transcribed with iScript cDNA kit (BioRad, Hercules, CA) according to the manufacturer's instruction. PCR was carried out for 25 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min using ReadyMix Taq polymerase (Sigma) with primers for human NAG-1 and GAPDH as follows: NAG-1: forward 5#-ctccag attccgagagttgc-3#, and reverse 5#-agagatacgcaggtg caggt-3#; GAPDH: forward 5#-gggctgcttttaactct ggt-3#, and reverse 5#-tggcaggtttttctagacgg-3#.
Western Blot Analysis
Western blot was performed as described previously (14) . Briefly, the cell lysates were obtained using RIPA buffer containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 5 lg/ml aprotinin, and 5 lg/ml leupeptin) and phosphatase inhibitors (1 mM Na 3 VO 4 , 1 mM NaF). Protein concentration was determined by bicinchoninic acid protein assay (Pierce, Rockford, IL) using bovine serum albumin as the standard. The proteins were separated on sodium dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose membranes (Osmonics, Minnetonka, MN). The membranes were incubated with a specific primary antiserum in Tris-buffered saline containing 0.05% Tween 20 and 5% non-fat dry milk at 4°C overnight. After three washes with Tris-buffered saline containing 0.05% Tween 20, the blots were incubated with peroxidase-conjugated immunoglobulin G for 1 h at room temperature and visualized using ECL (Amersham Biosciences, Piscataway, NJ).
Immunoprecipitation
For detection of phosphor C/EBPb, the cells were sonicated five times for 10 s and the cell lysates were precleared using Protein A/G-agarose beads (Santa Cruz) and then pulled down with C/EBPb antibody for overnight. For immunoprecipitation of GSK3b and C/EBPb, each expression vector was transfected into HCT-116 cells, and cell lysates were pulled down using Probond nickel resin (Invitrogen). Co-purified proteins were analyzed by immunoblotting using specific antibodies for V5, GSK3b, C/EBPb, and ATF3.
RNA interference
Interference for GSK3b was performed as described previously (14) . Briefly, 100 nM of GSK-3 siRNA or control siRNA was transfected using TransIT-TKO transfection reagent (Mirus, Madison, WI) for 24 h. For interference of C/ EBPb, the 3 lg of control or C/EBPb shRNA was transfected using Lipofectamine 2000 (Invitrogen) for 48 h. For interference of ATF3, 200 nM of siATF3 or control siRNA was transfected using TransIT-TKO transfection reagent for 48 h.
Electrophoretic mobility shift assay HCT-116 cells were grown to reach 80% confluence in 100-mm plates. After serum starvation overnight, the cells were treated with ethanol or 50 lM of capsaicin for 6 h. After washing with PBS, nuclear extracts were prepared following the manufacturer's protocols (Active Motif, Carlsbad, CA). The electrophoretic mobility shift assay was performed as we described previously (12) . Oligonucleotide probes contained the following sequences: NAG-1-110/-103: 5'-gctgtggtcattgctgtggtcattgctgtggtcatt -3' and NAG-1-87/-80: 5#-tctgcaggcaggtctgcaggca ggtctgcaggcagg-3#. Biotin-labeled oligonucleotide (100 nM) was incubated with nuclear protein (5 lg) and 1Â binding buffer (Promega) at room temperature for 20 min. For C/EBPb synthesis, in vitro translation was performed using TNT Quick Coupled Transcription/Translation Systems (Promega) per the manufacturer's protocol. For competition assay, nuclear proteins (5 lg) or in vitro synthesized C/EBPb was preincubated with the unlabeled oligonucleotide (10-or 100-fold) for 10 min.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay was performed as we described previously (12) . Briefly, the cells were fixed with 1% formaldehyde for 10 min at 37°C and sonicated four times for 10 s. The cell lysates (0.2 ml) were diluted with immunoprecipitation buffer (1.8 ml) and immunoprecipitated with 5 lg of specific antibodies for immunoglobulin G, C/EBPa, C/EBPb, RARa, CREB, and ATF3 at 4°C for overnight. The chromatin-associated DNA was eluted, reverse cross-linked by heating at 65°C for 4 h and treated with proteinase K at 45°C for 2 h. DNA was purified by phenol/choloroform extraction, and precipitated DNA was amplified using the following primer pairs: forward, 5#-caccccc agaccccgcccagctgtggtcattg-3# and reverse, 5#-cttgcgcggctcgcctcggccagagacagggcgccccc-3#. PCR products (268 bp) were separated using a 2% agarose gel and visualized by ethidium bromide staining.
Statistical analysis
Statistical analysis was performed with the Student's unpaired t-test.
Results
Capsaicin suppresses cell growth, increases apoptosis and NAG-1 expression in human colorectal cancer cells To observe whether capsaicin affects growth of human colorectal adenocarcinoma cells, we treated HCT-116 cells with different concentrations of capsaicin and measured cell growth. As shown in Fig. 1A , treatment of 50 and 100 lM capsaicin for 24 h showed changes of cell morphology as well as decreased cell number (upper panel) and led to a significant decrease of cell growth (lower panel). These results are from capsaicin-induced cell death because the number of apoptotic cells significantly increased in the groups treated with 50 and 100 lM of capsaicin for 24 h in a dose-dependent manner ( Figure 1B ). To investigate whether capsaicin affects NAG-1 expression, HCT-116 cells were incubated with 0, 10, 50 and 100 lM of capsaicin for 24 and 48 h. As shown in Figure 1C (upper panel), NAG-1 protein levels increased in the cells treated with 50 lM of capsaicin at 24 and 48 h. It has been known that capsaicin increases p53 expression (25) S.-H. Lee et al. and NAG-1 is a p53-target gene (17, 19) , but capsaicin treatment does not increase p53 expression in HCT-116 cells (p53 wild-type). The NAG-1 mRNA level also increased in capsaicin-treated cells in a dosedependent manner ( Figure 1C , lower panel), suggesting that capsaicin affects NAG-1 expression at the transcription level. In the presence of 50 lM of capsaicin, NAG-1 protein began to increase at 6 h and showed a time-dependent induction ( Figure 1D ). Capsaicin treatment increased NAG-1 in LoVo (p53 wild) and HT-29 (p53 mutant) cells, but not in SW480 (p53 mutant) cells ( Figure 1E ), indicating cell specificity of capsaicin effects on cell growth in a p53-independent manner. To examine the relevance of the NAG-1 expression to apoptosis by capsaicin, we knocked down the NAG-1 gene and then measured apoptosis. As shown in Figure 1F , knockdown of NAG-1 ameliorated induction of apoptosis by capsaicin treatment.
C/EBPb mediates capsaicin-induced NAG-1 expression
To investigate the molecular mechanism of capsaicin-induced NAG-1 expression, a deletion assay using the human NAG-1 promoter was performed to observe whether capsaicin affects transcriptional regulation of the NAG-1 gene. As shown in Figure 2A , 50 lM of capsaicin treatment resulted in the stimulation of NAG-1 promoter activity in all the constructs tested, implying that the responsible cognate site by capsaicin is located between the À133 and þ41 regions. The NAG-1 promoter containing the p53 binding site (pNAG-1-133/þ70) showed similar activity with other promoters that do not contain p53 binding site, confirming that capsaicin-induced NAG-1 expression is p53 independent. This is consistent with the data that p53 expression was not altered by capsaicin treatment ( Figure 1C) .
The À133 and þ41 region contains multiple putative transcription factor-binding sites including C/EBPs, Sp1, and RARa. To find the trans-acting elements responsible for NAG-1 transactivation, we cloned or obtained several expression vectors for C/EBPb, C/EBPa, C/EBPd, CREB, CHOP (C/EBPf), and RARa ( Figure 2B , left panel). CHOP and CREB could also bind to the C/EBP binding sites. Indicated expression vectors were cotransfected with the NAG-1 promoter constructs (pNAG-1À133/þ41) and luciferase activity was determined. As a result, only C/EBPb expression caused a dramatic increase of basal and capsaicin-induced luciferase activity ( Figure 2B , right panel). In addition, the chromatin immunoprecipitation assay confirmed C/EBPb as a binding protein to the À133/þ41 region of the NAG-1 promoter ( Figure 2C ). Interestingly, RARa also binds to this region, but RARa expression itself does not increase basal and (14) and then treated with 100 lM capsaicin for 24 h. The validation of NAG-1 knockdown is indicated (upper panel). Apoptosis was analyzed using propidium iodide staining as described in Materials and Methods (lower panel).
Capsaicin and NAG-1 in human colorectal cancer capsaicin-induced NAG-1 promoter activity ( Figure 2B, right panel) . To further identify potential regulatory cis-acting elements mediating capsaicin effects, we constructed internal deletion clones lacking potential binding sites for both C/EBPs. Since C/EBPb binds to this region and its expression results in NAG-1 promoter activity ( Figure 2B and C), the cells were transfected with wild-type or deletion constructs lacking C/EBPb binding sites and treated with 50 lM of capsaicin for 24 h. As shown in Figure 2D , deletion of the distal C/EBP binding site (À110/À103) slightly decreased capsaicin's effect, whereas deletion of the proximal C/EBP binding site (À87/À80) did not affect luciferase activity. Unexpectedly, capsaicin's effect was completely abolished in cells transfected with a double deletion promoter construct lacking both distal and proximal C/EBP binding sites. These data suggest that these two binding sites are necessary for NAG-1 promoter activation by capsaicin treatment.
GSK3b-and PKC-mediated phosphorylation of C/EBPb induces NAG-1 expression
To gain further insight into signaling factors regulating NAG-1 expression by capsaicin, HCT-116 cells were pretreated with vehicle (dimethyl sulfoxide) or different kinase inhibitors for 30 min and incubated with 50 lM capsaicin. Pretreatment of cells with RO-31-8220 (PKC inhibitor) and AR-A014418 (selective GSK3 inhibitor) abolished capsaicin-induced NAG-1 expression, suggesting that these pathways mediate capsaicin-induced NAG-1 expression ( Figure 3A) . Since NAG-1 expression is mediated by PKCd in prostate cancer cells (26) , we tested the effect of rottlerin (a PKCd-selective inhibitor) on NAG-1 expression. Pretreatment of rottlerin abolished capsacininduced NAG-1 activation (Figure 3B ), indicating an involvement of PKCd on capsaicin-induced NAG-1 expression. Next, to confirm the possible regulatory effect of GSK3b on capsaicin-induced NAG-1 expression, the cells were transfected with GSK3b siRNA, followed by capsaicin treatment. Knockdown of GSK3b attenuated NAG-1 induction by capsaicin ( Figure 3C ), indicating that GSK3b plays an important role in capsaicin-induced NAG-1 expression.
Furthermore, we measured the phosphorylated serine/threonine form of C/EBPb using immunoprecipitation to see whether capsaicin affects phosphorylation of C/EBPb protein. The cells were treated with capsaicin, and pulled down with C/EBPb antibody, followed by immunoblot with antibody against phosphor serine/threonine or Figure 3D , capsaicin treatment induced phosphorylated serine/threonine residues on C/EBPb, providing evidence that capsaicin enhances the phosphorylation of C/EBPb. We further examined whether phosphorylation of C/EBPb is mediated by PKC and GSK3b. As shown in Figure 3E , phosphorylation of C/EBPb by capsaicin was inhibited in the presence of inhibitors of these pathways, supporting that C/EBPb is a target transcription factor of PKC and GSK3b. We also tested whether capsaicin increases phosphorylation of C/EBPb at early time point. The results show that capsaicin did not affect C/EBPb phosphorylation after exposure to capsaicin for 2 h ( Figure 3E ).
C/EBPb. As shown in
Binding activity of C/EBPb on the NAG-1 promoter
Results from promoter analyses indicated that two potential C/EBPb binding sites are necessary to activate luciferase activity of the NAG-1 promoter ( Figure 2D ). To observe the association of C/EBPb with the NAG-1 promoter, we carried out electrophoretic mobility shift assay using nuclear proteins with a biotin-labeled DNA probe corresponding to À110 to À103 (À110/À103) and À87 to À80 (À87/À80) of NAG-1 promoter. DNA-protein complex formation was enhanced by capsaicin treatment in oligonucleotides of À110/À103, whereas this increase was relatively smaller using an À87/À80 probe ( Figure 4A ). Preincubation of nuclear extracts with 10Â and 100Â cold oligonucleotide inhibited the binding activity in both oligonucleotides ( Figure 4B, lanes 3-4, 7-8) , suggesting that the binding protein is sequence specific. To test whether C/EBPb binds to this oligonucleotide, in vitro translated C/EBPb protein was incubated with the probe. As a result, C/EBPb interacted with the NAG-1 promoter, and this interaction was inhibited by the addition of 10Â or 100Â cold oligonucleotides (Figure 4C ), confirming the binding of C/EBPb to these sequences.
Association of C/EBPb with GSK3b and ATF3
GSK3b activity is mainly regulated by phoshorylation, transcriptional level, or cellular localization (27) . To gain further information of how capsaicin affects GSK3b activation, we compared expression of GSK3b proteins using immunoblot analysis. Interestingly, capsaicin treatment increased total protein levels of GSK3b ( Figure 5A ). The mRNA level of GSK3b was also increased (data not shown). It is notable that GSK3b expression begins to increase at 6 h time point ( Figure 5B), when NAG-1 expression begins to increase ( Figure 1D ). Next, we examined GSK3b cellular localization because it has been known that apoptotic signals increase nuclear accumulation of GSK3b and their target genes are activated (28, 29) . As shown in Figure 5C , capsaicin treatment caused increased accumulation of GSK3b in the nucleus. These results suggest that capsaicin enhances the expression of GSK3b, thereby accumulating nuclear GSK3b protein and provide the hypothesis that GSK3b may directly associate and phosphorylate C/EBPb in the nucleus in the presence of capsaicin. To investigate the possibility of direct physical interaction between C/EBPb and GSK3b, we used histidine tag pull-down assays, followed by western blot after transient transfection of C/EBPb expression vector (pcDNA3.1/C/EBPb2/V5/His) in the presence of capsaicin. As shown in Figure 5D , capsaicin treatment increases protein-protein interaction between GSK3b and C/EBPb. These interactions can be suppressed by the inhibition of PKC and GSK3b pathways ( Figure 5E ).
On the other hand, our previous studies showed that ATF3 plays an important role in the NAG-1 induction (14, 18) , and recent other studies demonstrated that ATF3 and C/EBPb may act in concert to regulate their target gene (30, 31 ). Interestingly, nuclear ATF3 level was increased after capsaicin treatment ( Figure 5C ). Thus, we examined ATF3 protein as an interacting protein with C/EBPb in capsaicininduced NAG-1 expression. As shown in Figure 5D , C/EBPb2 is able to associate with ATF3 at the basal level and capsaicin treatment increases interaction between C/EBPb and ATF3. Interestingly, this interaction was also inhibited in the presence of GSK3b and PKC inhibitors ( Figure 5E ), indicating that interaction of C/EBPb with ATF3 depends on its phosphorylation. However, incubation with capsaicin for 2 h did not affect formation of transcription factor complex ( Figure 5E ). 
Capsaicin and NAG-1 in human colorectal cancer
To confirm the interaction of GSK3b with C/EBPb and ATF3, the reverse immunoprecipitation using V5 antibody for GSK3b pull down and C/EBPb or ATF3 antibodies for immunoblotting was performed in the same way. The association of GSK3b with C/EBPb and ATF3 could be detected in basal level and this association was induced by capsaicin treatment ( Figure 5F ).
Chromatin immunoprecipitation assay was performed to see whether ATF3 is associated with formation of complex, which binds to the NAG-1 promoter. As shown in Figure 5G , ATF3 associated with NAG-1 promoter. Since electrophoretic mobility shift assay indicated that ATF3 did not bind directly to the NAG-1 promoter (data not shown), it is likely that ATF3 is involved in formation of complex with C/EBPb, thereafter enhancing capsaicin-induced NAG-1 expression.
Knockdown of C/EBPb blocks capsaicin-induced NAG-1 expression and apoptosis
Finally, we tested whether C/EBPb and ATF3 are required for the induction of NAG-1 in response to capsaicin. The cells were transfected with control or C/EBPb shRNA and then treated with 50 lM capsaicin. Western blot confirmed complete knockdown of C/EBPb expression ( Figure 6A ). NAG-1 expression was increased in capsaicin-treated cells; however, C/EBPb shRNA-transfected cells completely abolished capsaicin-induced NAG-1 expression ( Figure 6A ). To examine whether C/EBPb has any relevance to the induction of apoptosis by capsaicin, we blocked C/EBPb expression, and apoptosis analysis was performed by flow cytometry. As shown in Figure 6B , fold increase of apoptosis by capsaicin was lower in C/EBPb shRNAtransfected cells compared with control vector-transfected cells (1.8-fold versus 3.5-fold; P , 0.001), suggesting a pivotal role of C/EBPb expression in capsaicin-induced apoptosis in HCT-116 cells. We also examined the role of ATF3 in capsaicin-induced NAG-1 expression using ATF3 siRNA. As shown in Figure 6C , knockdown of the ATF3 gene suppressed capsaicin-induced NAG-1 expression, demonstrating a significant role of ATF3 in NAG-1 expression in response to capsaicin treatment.
Discussion
In this study, we report that capsaicin increases apoptosis and activates proapoptotic gene NAG-1 through C/EBPb activation in human colorectal cancer cells. We also demonstrate a novel pathway that phosphorylation of C/EBPb by GSK3b and PKC in the presence of capsaicin is associated with a bZIP protein, ATF3.
The relevance of the NAG-1 gene in apoptosis and cell proliferation by several phytochemicals and chemopreventive drugs has been reported in various cancer models (9, 13, 14, 26) . We also observed that NAG-1 induction is implicated in apoptotic activity by capsaicin in human colorectal cancer cells ( Figure 1F ). Capsaicin-induced cell growth arrest and induction of NAG-1 expression was observed at 50 lM in HCT-116 cells. A low dose (10 lM) of capsaicin is effective to inhibit cell proliferation in endothelial cancer cells (32) , whereas a much higher concentration of capsaicin is required to induce apoptosis in colorectal cancer cells (8) , prostate cancer cells (2) , and gastric carcinoma cells (33) .
In terms of physiological concentration of capsaicin, blood concentration of capsaicin was estimated to be 581 ng/ml (equivalent to 2 lM) after intravenous administration of 2 mg capsaicin per kg body wt to rats (34) , and topical application of capsaicin resulted in blood capsaicin concentrations up to 10-20 lM (35). According to a recent human study, blood concentration of capsaicin is estimated at 2.47 ng/ml (equivalent to 8.1 nM) in male adults, after administrating 0.4 mg capsaicin per kg body wt (36) . However, actual daily intake of capsaicin in the countries that use more chili peppers is much higher (estimated at 2.8 mg/kg body wt) (37, 38) . Although the concentration of capsaicin (50 lM) we used is higher than plasma levels, we believe that a much higher amount of capsaicin could reach the lumen of the S.-H. Lee et al. gastrointestinal tract. This can be observed in other phytochemicals such as epigallocatechin gallate, which has a concentration 28-165 times higher in the gastrointestinal tract than in plasma (39) .
The transcriptional regulation of NAG-1 gene is mediated by several mechanisms, including p53 tumor suppressor gene (17, 19) , and early growth response gene-1 (12, 20) pathways. It has been reported that capsaicin induces apoptosis through a p53-dependent pathway in stomach cancer and leukemia cells (5, 25) . However, in colorectal cancer cells, it is unlikely that capsaicin-induced NAG-1 expression is p53 dependent, although NAG-1 is a target of p53 tumor suppressor gene.
Our data showed that knockdown of C/EBPb suppressed capsaicininduced NAG-1 expression ( Figure 6A ). These results, together with the observations that overexpression of C/EBPb is associated with the activation of the NAG-1 promoter ( Figure 2B ) implicate a crucial role of C/EBPb in NAG-1 induction by capsaicin. Thus, NAG-1 appears to be one of the target genes for C/EBPb transcription factor. C/EBPb seems to play a role in promoting tumorigenesis in some cancer models, including breast (40) and prostate (41) . For colorectal cancer, overexpression of C/EBPb protein results in cellular growth arrest and apoptosis (42) , although C/EBPb expression is increased in human colorectal cancer (43) . It remains unclear how C/EBPb is involved in tumor suppression through its interaction with specific downstream genes in cancer cells. Our data demonstrate that C/EBPb phosphorylation modulates recruitment of proapoptotic protein such as ATF3, enhancing its activity in NAG-1 expression.
The current data show that phosphorylation of C/EBPb by capsaicin is positively regulated by GSK3b pathway. Although we did not examine the changes of all phosphor form of C/EBPb in this study, it has been shown that GSK3b phosphorylates C/EBPb on Ser 177 , Ser 181 , Ser 185 , and Thr 189 residues (44) . Although phosphorylation of C/EBPb is regulated by GSK3b (44) (45) (46) in many types of cells, the detailed mechanisms are not fully elucidated. In this study, capsaicin treatment not only caused an increased expression of GSK3b but also increased accumulation of GSK3b in nuclear fraction ( Figure 5A-C) . In addition, the nuclear GSK3b directly associates with C/EBPb ( Figure 5D-F) . Thus, our data suggest that capsaicininduced overexpression of GSK3b results in the direct interaction with C/EBPb and subsequent phosphorylation of C/EBPb. Indeed, GSK3b increases rapidly early in the process of apoptosis and is able to modulate gene expression through its regulation of transcription factor (28) . We observed that capsaicin induced GSK3b mRNA (data not shown), implying transcriptional regulation of GSK3b by capsaicin. Further study is required to obtain more detailed information on how capsaicin regulates GSK3b gene expression.
Like other C/EBP members, C/EBPb phosphorylation at several serine and threonine residues allows recruitment of the transcriptional coactivator (47) . C/EBPb is able to form heterodimers, and such interactions alter DNA binding affinity and gene transcription. In fact, Capsaicin and NAG-1 in human colorectal cancer C/EBPb has been shown to interact with non-bZIP proteins such as p50 subunit of nuclear factor-kappaB, glucocorticoid receptor, and retinoblastoma protein (48) (49) (50) (51) . Such heterodimerization indicates different transactivation potential and DNA binding affinity/specificity. Another interesting finding of this study is that ATF3 may cause NAG-1 expression, at least in part, through the recruitment of C/EBPb. Although ATF3 does not bind to the NAG-1 promoter directly, the C/EBPb-ATF3 complex would be an important factor for capsaicin-induced NAG-1 expression. These observations interpret direct evidence to support the importance of ATF3 in increased DNA-binding potential of C/EBPb, which consequently mediates enhancement of C/EBPb-driven transactivation of the NAG-1 gene. One speculation would be that ATF3 may play a role as a bridge protein that facilitates recruitment of C/EBPb to the NAG-1 promoter during its activation. Despite the predominant cooperative regulation of C/EBPb, until now the question of whether ATF3 interacts with other transcription factors has not been addressed in the literature. Indeed, the fact that double deletion of C/EBP binding sites are required to abolish luciferase activity of capsaicin-induced NAG-1 expression supports this hypothesis. Secondly, capsaicin may lead to the formation of a supracomplex, including C/EBPb, ATF3 and other transcription factors because C/EBP dimers are able to be cross-coupled to other transcription factors and show DNA-binding characteristics distinct from those of the individual transcription factor partners (52) .
Our additional finding is that protein-protein interactions among GSK3b, C/EBPb, and ATF3 were inhibited by pretreatment of GSK3b selective inhibitor ( Figure 5E ). These data suggest that phosphorylation of C/EBPb by capsaicin increases recruitment of ATF3 for binding to C/EBPb, which subsequently increases NAG-1 gene transcription. With respect to other kinase pathways, we observed that PKCd is another mediator of C/EBPb phosphorylation and NAG-1 induction by capsaicin ( Figure 3 ). This is consistent with a previous study, showing that PKCd targets NAG-1 gene transcription (26) and other proapoptotic signaling pathways in many cancer models (53, 54) .
We evaluated the effect of capsaicin on C/EBPb phosphorylation and formation of transcription complex after shorter incubation (2 h) with capsaicin ( Figures 3E and 5E ). The results show that capsaicin did not affect C/EBPb phosphorylation or complex formation at 2 h. It is notable that C/EBPb phosphorylation usually occurs at a late time point (4-6 h) after stimulation (45, 55) . However, we do not exclude the possibility that C/EBPb phophorylation occurs via different signaling (GSK3b, PKC, or other kinase). It is still unclear how complex alterations including C/EBPb and ATF3 are able to participate in NAG-1 induction, but upon cellular activation by capsaicin, it is speculated that phosphorylation of C/EBPb enhances the formation of the transcriptional complex with ATF3 and DNA binding affinity to the promoter regions because C/EBPb at the resting state has weak DNA binding activity due to an intramolecular inhibitory element, whereas the phosphorylation of C/EBPb releases the intramolecular inhibition and exposes the DNA binding site (56) . In conclusion, capsaicin activates the transcription of the NAG-1 gene by activation of the C/EBPbdependent pathway. GSK3b modulates C/EBPb phosphorylation by direct protein-protein interaction, and activation of C/EBPb increases the binding affinity of C/EBPb onto the NAG-1 promoter and increases transcription of NAG-1 genes. In this serial sequence, ATF3 may facilitate the recruitment of C/EBPb to the NAG-1 promoter, and PKCd also affects phosphorylation of C/EBPb ( Figure 6D ). 
